Arcturus Therapeutics(ARCT) - 2025 Q1 - Quarterly Results

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 "We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to provide meaningful Phase 2 interim da ...